267 related articles for article (PubMed ID: 23392356)
1. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib.
Albers C; Leischner H; Verbeek M; Yu C; Illert AL; Peschel C; von Bubnoff N; Duyster J
Leukemia; 2013 Jun; 27(6):1416-8. PubMed ID: 23392356
[No Abstract] [Full Text] [Related]
2. Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.
Kancha RK; Grundler R; Peschel C; Duyster J
Exp Hematol; 2007 Oct; 35(10):1522-6. PubMed ID: 17889720
[TBL] [Abstract][Full Text] [Related]
3. Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.
Baker SD; Zimmerman EI; Wang YD; Orwick S; Zatechka DS; Buaboonnam J; Neale GA; Olsen SR; Enemark EJ; Shurtleff S; Rubnitz JE; Mullighan CG; Inaba H
Clin Cancer Res; 2013 Oct; 19(20):5758-68. PubMed ID: 23969938
[TBL] [Abstract][Full Text] [Related]
4. FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations.
Fathi AT; Chabner BA
Oncologist; 2011; 16(8):1162-74. PubMed ID: 21765192
[TBL] [Abstract][Full Text] [Related]
5. Bis(1H-indol-2-yl)methanones are effective inhibitors of FLT3-ITD tyrosine kinase and partially overcome resistance to PKC412A in vitro.
Heidel F; Lipka DB; Mirea FK; Mahboobi S; Grundler R; Kancha RK; Duyster J; Naumann M; Huber C; Böhmer FD; Fischer T
Br J Haematol; 2009 Mar; 144(6):865-74. PubMed ID: 19183186
[TBL] [Abstract][Full Text] [Related]
6. FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.
Pratz KW; Sato T; Murphy KM; Stine A; Rajkhowa T; Levis M
Blood; 2010 Feb; 115(7):1425-32. PubMed ID: 20007803
[TBL] [Abstract][Full Text] [Related]
7. The role of quizartinib in the treatment of acute myeloid leukemia.
Ostronoff F; Estey E
Expert Opin Investig Drugs; 2013 Dec; 22(12):1659-69. PubMed ID: 24070241
[TBL] [Abstract][Full Text] [Related]
8. MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia.
Xu B; Zhao Y; Wang X; Gong P; Ge W
Leukemia; 2017 Apr; 31(4):913-921. PubMed ID: 27773927
[TBL] [Abstract][Full Text] [Related]
9. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
Luskin MR; DeAngelo DJ
Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
[TBL] [Abstract][Full Text] [Related]
10. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.
Smith CC; Wang Q; Chin CS; Salerno S; Damon LE; Levis MJ; Perl AE; Travers KJ; Wang S; Hunt JP; Zarrinkar PP; Schadt EE; Kasarskis A; Kuriyan J; Shah NP
Nature; 2012 Apr; 485(7397):260-3. PubMed ID: 22504184
[TBL] [Abstract][Full Text] [Related]
11. Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia.
Swords R; Freeman C; Giles F
Leukemia; 2012 Oct; 26(10):2176-85. PubMed ID: 22614177
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells.
Stölzel F; Steudel C; Oelschlägel U; Mohr B; Koch S; Ehninger G; Thiede C
Ann Hematol; 2010 Jul; 89(7):653-62. PubMed ID: 20119833
[TBL] [Abstract][Full Text] [Related]
13. FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.
von Bubnoff N; Engh RA; Aberg E; Sänger J; Peschel C; Duyster J
Cancer Res; 2009 Apr; 69(7):3032-41. PubMed ID: 19318574
[TBL] [Abstract][Full Text] [Related]
14. Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.
Alvarado Y; Kantarjian HM; Luthra R; Ravandi F; Borthakur G; Garcia-Manero G; Konopleva M; Estrov Z; Andreeff M; Cortes JE
Cancer; 2014 Jul; 120(14):2142-9. PubMed ID: 24737502
[TBL] [Abstract][Full Text] [Related]
15. Leukemogenic potency of the novel FLT3-N676K mutant.
Huang K; Yang M; Pan Z; Heidel FH; Scherr M; Eder M; Fischer T; Büsche G; Welte K; von Neuhoff N; Ganser A; Li Z
Ann Hematol; 2016 Apr; 95(5):783-91. PubMed ID: 26891877
[TBL] [Abstract][Full Text] [Related]
16. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.
Smith CC; Lasater EA; Zhu X; Lin KC; Stewart WK; Damon LE; Salerno S; Shah NP
Blood; 2013 Apr; 121(16):3165-71. PubMed ID: 23430109
[TBL] [Abstract][Full Text] [Related]
17. Internal tandem duplication of FLT3 deregulates proliferation and differentiation and confers resistance to the FLT3 inhibitor AC220 by Up-regulating RUNX1 expression in hematopoietic cells.
Hirade T; Abe M; Onishi C; Taketani T; Yamaguchi S; Fukuda S
Int J Hematol; 2016 Jan; 103(1):95-106. PubMed ID: 26590920
[TBL] [Abstract][Full Text] [Related]
18. Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia.
Pemmaraju N; Kantarjian H; Andreeff M; Cortes J; Ravandi F
Expert Opin Investig Drugs; 2014 Jul; 23(7):943-54. PubMed ID: 24749672
[TBL] [Abstract][Full Text] [Related]
19. CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML.
Waldeck S; Rassner M; Keye P; Follo M; Herchenbach D; Endres C; Charlet A; Andrieux G; Salzer U; Boerries M; Duyster J; von Bubnoff N
Mol Oncol; 2020 Apr; 14(4):779-794. PubMed ID: 31955503
[TBL] [Abstract][Full Text] [Related]
20. Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.
Weisberg E; Meng C; Case AE; Sattler M; Tiv HL; Gokhale PC; Buhrlage SJ; Liu X; Yang J; Wang J; Gray N; Stone RM; Adamia S; Dubreuil P; Letard S; Griffin JD
Br J Haematol; 2019 Nov; 187(4):488-501. PubMed ID: 31309543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]